RallyBio is steering around more tight corners as it announces a further 40% reduction in staffers just weeks after ...

GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R ...

California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and ...

Charles River CEO James Foster had previously attributed the 2024 revenue dip to decreased demand from biopharma clients. In ...

Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic ...

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its ...

Marea Therapeutics has linked its lead candidate to a 53% placebo-adjusted mean reduction in remnant cholesterol, positioning ...

GE HealthCare has obtained the FDA’s blessing for its latest imaging system combining SPECT and CT scanning, as well as for ...

Neurocrine Biosciences has handed back two discovery-stage gene therapy programs to Voyager Therapeutics, although the ...

Mersana Therapeutics only has eyes for Emi-Le. Seeking to extend its cash runway into mid-2026, the biotech is laying off 55% ...

The National Institutes of Health (NIH) has laid off 250 more employees, with this round of cuts hitting 50 workers at the ...